ultomiris solution
alexion pharma gmbh - ravulizumab - solution - 1100mg - ravulizumab 1100mg
neisvac-c suspension
pfizer canada ulc - meningococcal polysaccharide vaccine grp c; tetanus toxoid - suspension - 10mcg; 20mcg - meningococcal polysaccharide vaccine grp c 10mcg; tetanus toxoid 20mcg - vaccines
nimenrix kit
pfizer canada ulc - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group w-135; meningococcal polysaccharide antigen group y; tetanus toxoid - kit - 5mcg; 5mcg; 5mcg; 5mcg; 44mcg - meningococcal polysaccharide antigen group a 5mcg; meningococcal polysaccharide antigen group c 5mcg; meningococcal polysaccharide antigen group w-135 5mcg; meningococcal polysaccharide antigen group y 5mcg; tetanus toxoid 44mcg - vaccines
bexsero suspension
glaxosmithkline inc - recombinant neisseria meningitidis group b nhba fusion protein; recombinant neisseria meningitidis group b nada protein; recombinant neisseria meningitidis group b fhbp fusion protein; outer membrane vesicles (neisseria meningitidis group b nz98/254 strain) - suspension - 50mcg; 50mcg; 50mcg; 25mcg - recombinant neisseria meningitidis group b nhba fusion protein 50mcg; recombinant neisseria meningitidis group b nada protein 50mcg; recombinant neisseria meningitidis group b fhbp fusion protein 50mcg; outer membrane vesicles (neisseria meningitidis group b nz98/254 strain) 25mcg - vaccines
trumenba suspension
pfizer canada ulc - neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily a; neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily b - suspension - 60mcg; 60mcg - neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily a 60mcg; neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily b 60mcg - vaccines
menquadfi solution
sanofi pasteur limited - meningococcal group a polysaccharide-tetanus toxoid conjugate; meningococcal group c polysaccharide-tetanus toxoid conjugate; meningococcal group y polysaccharide-tetanus toxoid conjugate; meningococcal group w polysaccharide-tetanus toxoid conjugate; tetanus toxoid - solution - 10mcg; 10mcg; 10mcg; 10mcg; 55mcg - meningococcal group a polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group c polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group y polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group w polysaccharide-tetanus toxoid conjugate 10mcg; tetanus toxoid 55mcg - vaccines
idefirix 11 mg
medison pharma ltd - imlifidase - powder for concentrate for solution for infusion - imlifidase 11 mg/vial - imlifidase - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.
empaveli solution
swedish orphan biovitrum ab (publ) - pegcetacoplan - solution - 1080mg - pegcetacoplan 1080mg
soliris 300 mg vial 30 ml